Wave Life Sciences (NASDAQ:WVE) highlighted upcoming clinical catalysts across its obesity and RNA editing programs during a ...

At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted ...

Phase 1 data suggest that WVE-007, an investigational siRNA drug given by injection, leads to reductions in visceral fat, waist circumference, and body weight.

Shares of Wave Life Sciences WVE plunged 49.6% yesterday after the company announced new data from the phase I portion of the INLIGHT study evaluating its investigational pipeline candidate, WVE-007, ...

At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%;p<0.05) and total fat (-5%), stabilization o ...

On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and ...

The inaugural InLight sixteen years ago was held on a First Friday in September and attracted approximately 5,000 curious art lovers along Broad Street. The event’s nonprofit organizers, 1708 Gallery, ...

Melbourne-based digital services business Inlight has signalled its ambitions by appointing Adrian O’Dea to a newly created head of growth role. O’Dea joins from Telstra, where he led the creative ...

At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral ...

At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%; p WVE-007 led to greater improvement in ...